WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Epistemonikos ID: b0914001070efd4ac8bb9cec3c2ea0621626ae4e
First added on: May 14, 2025